Sutro Biopharma
STRO
112 hedge funds and large institutions have $40M invested in Sutro Biopharma in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 27 closing their positions.
30% more call options, than puts
Call options by funds: $35K | Put options by funds: $27K
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.41% less ownership
Funds ownership: 7.75% → 7.34% (-0.41%)
8% less funds holding
Funds holding: 122 → 112 (-10)
37% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 27
66% less capital invested
Capital invested by funds: $118M → $40M (-$77.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.98M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$2.83M |
| 3 |
EP
Eversept Partners
New York
|
+$2.52M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.18M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.04M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$3.97M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.65M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$3.18M |
| 5 |
BlackRock
New York
|
-$2.19M |
STRO Hedge Fund Activity: Q1 2025 in Review
112 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2025, worth a combined $40M — down 66% from $118M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of STRO and 17 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 38 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $6.98M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.04M sold.
- 112 institutional investors held Sutro Biopharma (STRO) as of Q1 2025, down from 122 in Q4 2024.
- Funds reported $40M of Sutro Biopharma stock for Q1 2025, down 66% quarter-over-quarter.
- 17 funds opened new Sutro Biopharma positions in Q1 2025 and 27 closed out, a net change of -10 holders.
- The largest Sutro Biopharma buyer in Q1 2025 was RA Capital Management, an estimated $6.98M added.
- The largest Sutro Biopharma seller in Q1 2025 was Point72 Asset Management, an estimated $4.04M sold.
Based on aggregated 13F filings for Q1 2025.